3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Breast
1
Conditions
Colorectal Neoplasms
23
Neoplasm Metastasis
14
Neoplasms
13
Rectal Neoplasms
8
Colorectal Cancer Metastatic
6
Ovarian Neoplasms
5
Lymphoma, Non-Hodgkin
5
Colonic Neoplasms
5
Uveal Melanoma
4
Sarcoma
4
Precursor Cell Lymphoblastic Leukemia-Lymphoma
4
Melanoma
4
Lymphoma, Mantle-Cell
4
Lymphoma, Large-Cell, Immunoblastic
4
Lymphoma, Large B-Cell, Diffuse
4
Lymphoma, Follicular
4
Lymphoma, B-Cell, Marginal Zone
4
Leukemia, Lymphocytic, Chronic, B-Cell
4
Fallopian Tube Neoplasms
4
Carcinoma, Ovarian Epithelial
4
Burkitt Lymphoma
4
Uterine Cervical Neoplasms
3
Urinary Bladder Neoplasms
3
Urethral Neoplasms
3
Stomach Neoplasms
3
Prostatic Neoplasms
3
Lung Neoplasms
3
Glioblastoma
3
Endometrial Neoplasms
3
Carcinoma, Renal Cell
3
Interventions
Gemcitabine
92
Cisplatin
70
Oxaliplatin
37
Capecitabine
37
durvalumab
29
Fluorouracil
26
pembrolizumab
24
Leucovorin
22
S 1 (combination)
18
Nivolumab
13
Irinotecan
13
Bevacizumab
13
lenvatinib
12
tremelimumab
10
apatinib
8
Trastuzumab
7
Injections
7
Albumin-Bound Paclitaxel
7
130-nm albumin-bound paclitaxel
7
Paclitaxel
6
Immune Checkpoint Inhibitors
6
Docetaxel
6
titanium silicide
5
surufatinib
5
envafolimab
5
camrelizumab
5
atezolizumab
5
Folfox protocol
5
Drug Therapy
5
Carboplatin
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Biliary Tract Neoplasms
×
aflibercept
×
Clear all
NCT01843725
2018-01-31
MOMENTUM1
Jules Bordet Institute
Phase 1
Completed
37 enrolled